Physician profile
Dennis Phan
NPI 1437238342
$7,178.13
in general payments reported to CMS, 2019-2025
32 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $902 · 2021: $1,526 · 2022: $1,231 · 2023: $1,035 · 2024: $674 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $31.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.90 |
| Education | $31.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,039.45 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $917.19 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $882.72 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $505.85 | 2019-2025 | Farxiga, Lokelma, Saphnelo |
| Opko Pharmaceuticals, LLC | $480.68 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $357.04 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.45 | 2021-2023 | |
| Glaxosmithkline, LLC. | $349.44 | 2020-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $308.86 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $277.19 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $272.60 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $266.53 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $234.49 | 2021-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $137.29 | 2022-2025 | |
| Novo Nordisk INC | $99.00 | 2021-2024 | Ozempic, Rybelsus |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $91.32 | 2023-2024 | Ibsrela |
| Akebia Therapeutics INC | $69.15 | 2019-2025 | Auryxia, Vafseo |
| Genzyme Corporation | $67.38 | 2019-2023 | |
| Daiichi Sankyo INC. | $65.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $59.19 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $56.85 | 2023 | Ultomiris |
| Mallinckrodt Enterprises LLC | $43.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.21 | 2022-2025 | Jardiance |
| Shire North American Group INC | $38.02 | 2019 | |
| Lilly USA, LLC | $35.19 | 2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $28.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.97 | 2020 | |
| Strongbridge US INC. | $21.23 | 2020 | |
| Kyowa Kirin, INC. | $15.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.74 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.75 | 2025 | Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $13.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.